Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 ...

Financial Data and Key Metrics - Record quarterly revenues of $4.1 million, up 61% compared to the same period last year [6] - Gross profit for Q1 2023 was $2 million, representing a gross margin of approximately 49%, up from 47% in the prior year [16] - Loss from operations in Q1 2023 was $4.4 million, compared to $4.2 million in the prior-year period [33] - Cash used in operating activities in Q1 2023 was $4.2 million, with a cash balance of $16.3 million as of March 31, 2023 [33] - Operating expenses for Q1 2023 were $6.4 million, up from $5.4 million in Q1 2022, primarily due to the acquisition of HMC and increased marketing activities [43] Business Line Performance - EksoHealth delivered $4 million in revenue in Q1 2023, driven by multi-unit orders with large network operators, including the second-largest EksoNR order ever [26] - EksoWorks revenue decreased by $0.6 million in Q1 2023, with a focus on transitioning towards volume purchases from large customers in industries such as construction, manufacturing, and green energy [49] - The newly acquired HMC business unit contributed modestly in Q1 2023, with expectations for stronger contributions as the year progresses [35] Market Performance - EMEA region grew 67% compared to Q1 2022, with the first Ekso Indego personal device sold in Europe during the quarter [27][28] - The company expanded its distribution network in EMEA through the acquisition of HMC, adding a commercial resource and strengthening partnerships [50] Strategic Direction and Industry Competition - The company is focused on driving sustainable growth across the continuum of care, leveraging its EksoHealth and Ekso Indego product lines [25][31] - Integration of HMC is progressing smoothly, with plans to merge market-leading technologies to deliver lower extremity rehab and mobility solutions [32] - The company is expanding its product development pipeline into the orthotic and prosthetic (O&P) industry, forming strategic relationships with key partners like Vanderbilt University [29] Management Commentary on Operating Environment and Future Outlook - Management highlighted strong demand for EksoHealth devices, including EksoNR and Ekso Indego, driven by the success of the commercial strategy [41] - The company anticipates continued growth in EMEA and plans to strengthen its sales and distribution network in the region [36][50] - Supply chain challenges have caused margin compression, but management expects improvements as the supply chain stabilizes [40][52] Other Important Information - The company reestablished its partnership with SoldierStrong, a charitable organization supporting veterans, and donated its 30th robotic exoskeleton to a VA Medical Center [10][11] - The cumulative conversion and renewal rate remained strong at 81%, with $1.4 million of contracted unrecognized revenue under the subscription model [8] Q&A Session Summary Question: Contribution of Indego in Q1 2023 - The contribution from Indego in Q1 2023 was relatively modest, but the company expects stronger contributions as the year progresses [35] Question: EMEA Growth and Sales Personnel - The company has a strong team in EMEA, with additional resources added through the HMC acquisition, and feels adequately resourced to support growth in the region [50] Question: Multi-Unit Orders in the US - The company is seeing more multi-unit opportunities in its pipeline, both in the US and internationally, and continues to grow relationships with network operators [51] Question: Potential for Margin Expansion - Management expects further margin expansion through supply chain improvements and cost reductions, with most supply chain challenges peaking or behind them [52] Closing Remarks - The company thanked employees and shareholders for their contributions and support, expressing optimism for continued growth and momentum [56]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Nevada 99-0367049 (I.R.S. Emp ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Steven Sherman - Chairman and Chief Executive Officer Scott Davis - President and Chief Operating Officer Jerome Wong - Chief Financial Officer Operator Greetings and welcome to Ekso Bionics Third Quarter 2022 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2022 Results Conference Call July 28, 2022 4:30 PM ET Company Participants David Carey - Head, Investor Relations Steven Sherman - Chairman & CEO Scott Davis - President & Chief Operating Officer Jerome Wong - interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Kyle Bauser - LakeStreet Capital Operator Hello, and welcome to the Ekso Bionics Q2 2022 Financial Results Conference Call. [Operator Instructions] As a re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Andrew Blazier - Finn Partners Steven Sherman - Chairman & CEO Scott Davis - President & Chief Operating Officer Jack Glenn - CFO Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio ...